Groupama Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $17.6M | Buy |
48,385
+8,246
| +21% | +$2.99M | 0.29% | 64 |
|
|
2025
Q1 | $12.5M | Buy |
40,139
+11,689
| +41% | +$3.64M | 0.25% | 67 |
|
|
2024
Q4 | $8.32M | Buy |
28,450
+7,065
| +33% | +$2.07M | 0.17% | 83 |
|
|
2024
Q3 | $6.13M | Sell |
21,385
-2,849
| -12% | -$817K | 0.16% | 96 |
|
|
2024
Q2 | $5.89M | Buy |
24,234
+21,978
| +974% | +$5.34M | 0.08% | 120 |
|
|
2024
Q1 | $3.25M | Sell |
2,256
-15,061
| -87% | -$21.7M | 0.06% | 173 |
|
|
2023
Q4 | $3.32M | Buy |
+17,317
| New | +$3.32M | 0.09% | 146 |
|